Aldosterone Receptor Antagonism Induces Reverse Remodeling When Added to Angiotensin Receptor Blockade in Chronic Heart Failure

Journal of the American College of Cardiology

Volumn 50, Issue 7, 2007, Pages 591-596

  Chan, Anna K Y ^a   Sanderson, John E ^a   Wang, Tian ^a   Lam, Wynnie ^a   Yip, Gabriel ^a   Wang, Mei ^a   Lam, Yat Yin ^a   Zhang, Yan ^a   Yeung, Leata ^a   Wu, Eugene B ^a   Chan, Wilson W M ^a   Wong, John T H ^a   So, Nina ^a   Yu, Cheuk Man ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; ALDOSTERONE RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRATE; SPIRONOLACTONE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ECHOCARDIOGRAPHY; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE VOLUME; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

AGED; ALDOSTERONE ANTAGONISTS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SPIRONOLACTONE; TETRAZOLES; TREATMENT OUTCOME; VENTRICULAR REMODELING;

EID: 34547555364     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2007.03.062     Document Type: Article

References (17)

1. Matsumura K., Fujji K., Oniki H., et al. Role of aldosterone in left ventricular hypertrophy in hypertension. Am J Hypertens 19 (2006) 13-18
2. Pitt B., Zannad F., Remme W.J., et al., Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341 (1999) 709-717
3. Struthers A.D. The clinical implications of aldosterone escape in congestive heart failure. Eur J Heart Failure 6 (2004) 539-545
4. Sato A., and Saruta T. Aldosterone breakthrough during angiotensin-converting enzyme inhibitor therapy. Am J Hypertens 16 (2003) 781-788
5. Cohn J.N., Anand I.S., Latini R., et al., Valsartan Heart Failure Trial Investigators. Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure. Circulation 108 (2003) 1306-1309
6. Naruse M., Tanabe A., Sato A., et al. Aldosterone breakthrough during angiotensin II receptor antagonist therapy in stroke-prone spontaneously hypertensive rats. Hypertension 40 (2002) 28-33
7. Yu C.M., Fung J.W.H., Zhang Q., et al. Tissue Doppler imaging is superior to strain rate imaging and postsystolic shortening on the prediction of reverse remodeling in both ischemic and nonischemic heart failure after cardiac resynchronization therapy. Circulation 110 (2004) 66-73
8. Nagueh S.F., Middleton K.J., Kopelen H.A., Zoghbi W.A., and Quinones M.A. Doppler tissue imaging: a noninvasive technique for evaluation of left ventricular relaxation and estimation of filling pressures. J Am Coll Cardiol 30 (1997) 1527-1533
9. Mottram P.M., Haluska B., Leano R., et al. Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation 110 (2004) 558-565
10. Sanderson J.E. New treatments for myocardial fibrosis. Cardiovasc Drugs Ther 16 (2002) 181-182
11. Fraccarollo D., Galuppo R., Schmidt I., et al. Additive amelioration of left ventricular remodeling and molecular alterations by combined aldosterone and angiotensin receptor blockade after myocardial infarction. Cardiovasc Res 67 (2005) 97-105
12. Brilla C.G., Zhou G., Matsubara L., et al. Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Mol Cell Cardiol 26 (1994) 809-820
13. Fung J.W., Yu C.M., Yip G., et al. Effect of beta-blockade (carvedilol or metoprolol) on activation of the renin-angiotensin-aldosterone system and natriuretic peptides in chronic heart failure. Am J Cardiol 92 (2003) 406-410
14. Young J.B., Dunlap M.E., Pfeffer M.A., et al. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation 110 (2004) 2618-2626
15. Yusuf S., Pfeffer M.A., Swedberg K., et al., CHARM Investigators and Committees. Effect of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 363 (2003) 777-781
16. Taniguchi I., Kawai M., Date T., et al. Effects of spironolactone during an angiotensin II receptor blocker treatment on the left ventricular mass reduction in hypertensive patients with concentric left ventricular hypertrophy. Circ J 70 (2006) 995-1000
17. Bellenger N.G., Davies L.C., Francis J.M., et al. Reduction of sample size for studies of remodeling in heart failure by the use of cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2 (2000) 271-278